HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- amino- 2- hydroxy- 4- phenylbutanoylvalylisoleucine

an aminopeptidase inhibitor; structure in first source

Also Known As:

3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine; 3-amino-HPBVI; LYRM03

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - 3-amino-2-hydroxy-4-phenylbutanoylvalylisoleucine: 4

Experts

1.	Liu, Qin: 1 article (03/2021)
2.	Lu, Daopeng: 1 article (03/2021)
3.	Qi, Na: 1 article (03/2021)
4.	Wang, Bin: 1 article (03/2021)
5.	Wang, Jiaoyue: 1 article (03/2021)
6.	Jiang, Qinghe: 1 article (11/2019)
7.	Shi, Yan: 1 article (11/2019)
8.	Wang, Shujuan: 1 article (11/2019)
9.	Du, Liang-Dong: 1 article (01/2019)
10.	Feng, Mei-Qing: 1 article (01/2019)

Related Diseases

1.	Acute Lung Injury 11/01/2019 - "3-amino-2-hydroxy-4-phenyl-valyl-isoleucine (LYRM03) has been shown to be beneficial in a rat model of acute lung injury (ALI). " 03/01/2021 - "The Defensive Action of LYRM03 on LPS-Induced Acute Lung Injury by NF-κB/TLR4/NLRP3 Signals." 03/01/2021 - "The aim of the current investigation was to study the role of 3-amino-2-hydroxy-4-phenyl-valyl-isoleucine (LYRM03) in lipopolysaccharide (LPS)-induced acute lung injury (ALI) and investigate its potential pathogenesis. " 03/01/2017 - "LYRM03, an ubenimex derivative, attenuates LPS-induced acute lung injury in mice by suppressing the TLR4 signaling pathway."
2.	Lung Injury 03/01/2017 - "LYRM03 may serve as a potential treatment for sepsis-mediated lung injuries." 03/01/2021 - "The extent of injury and lung injury scores in the LYRM03 (20 mg/kg) + siRNA targeting NF-κB p65, TLR4, or NLRP3 + LPS-treated rats were higher than that in the LYRM03 (20 mg/kg) + LPS-treated rats. "
3.	Sepsis (Septicemia) 03/01/2017 - "LYRM03 may serve as a potential treatment for sepsis-mediated lung injuries."
4.	Pneumonia (Pneumonitis) 11/01/2019 - "Posttreatment With LYRM03 Protects Rats From Acute Lung Inflammation Induced by Lipopolysaccharide via Suppressing the NF-κB/MyD88/TLR4 Axis."
5.	Neoplasms (Cancer) 01/01/2019 - "Because of its anti-metastasis capacity, further structure modifications of LYRM03 will be of interest for its use alone or in combination as a therapy in cancer."

Related Drugs and Biologics

1.	Lipopolysaccharides
2.	Small Interfering RNA (siRNA)
3.	Chemokines
4.	Peroxidase (Myeloperoxidase)
5.	ubenimex

Related Therapies and Procedures

1.	Therapeutics